Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13724095 | 0.84 | — | — | |
| SCHEMBL710380 | 0.80 | BRD4 (0.31) | APP | |
| SCHEMBL13842050 | 0.77 | PPARA (0.31) | — | |
| SCHEMBL23440355 | 0.77 | APLNR (0.30) | APLNR | |
| SCHEMBL13803857 | 0.76 | APP (0.33) | APP | |
| SCHEMBL6276420 | 0.76 | APP (0.33) | APP | |
| SCHEMBL714295 | 0.75 | PABPC1 (0.33) | APLNR | |
| SCHEMBL711781 | 0.75 | APLNR (0.32) | APLNR | |
| SCHEMBL713529 | 0.75 | APLNR (0.37) | APLNR | |
| SCHEMBL18883619 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 660 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120136817-A | Preparation method of oxetane-3-methanol and oxetane-3-formaldehyde | 安徽泽升科技股份有限公司 | 2025-06-13 | — | — | CN | claimed |
| US-20100022778-A1 | PROCESS FOR PRODUCTION OF SULFINYLBENZIMIDAZOLE COMPOUNDS OR SALTS THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-01-28 | — | — | US | claimed |
| WO-2008047849-A1 | PROCESS FOR THE PRODUCTION OF 2- [ [4- T (2, 2-DIMETHYL-1, 3-DIOXAN-5-YL) METHOXY] PYRIDIN-2-YL] METHYLTHIO] -1H-BENZIMIDAZOLE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-04-24 | — | — | WO | claimed |
| CN-122080069-A | Phospholipid compounds and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4482583-B1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-12583861-B2 | Derivatives of imidazo[4,5-d]pyridazine, their preparation and their therapeutic application | SANOFI (FR) | 2026-03-24 | — | — | US | disclosed |
| US-20260069539-A1 | LIPIDOID COMPOUNDS AND RELATED COMPOSITIONS AND USES | POSEIDA THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4004075-B1 | AQUEOUS CATIONIC POLYURETHANE DISPERSIONS | AGFA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| EP-4702044-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS WITH BIO-DISTRIBUTION MODIFIER | 3B Pharmaceuticals GmbH (DE) | 2026-03-04 | — | — | EP | disclosed |
| EP-4288438-B1 | DERIVATIVES OF IMIDAZO[4,5-D]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2026-02-18 | — | — | EP | disclosed |
| US-4672071-A | Antihypertensive dihydropyridine compositions, optical isomers and intermediates | SYNTEX (U.S.A.) INC. (US) | 1987-06-09 | — | — | US | disclosed |
| US-4659772-A | REACTION INJECTION MOLDED, HIGH RESILIENCY POLYURETHANE FOAMS | UNION CARBIDE CORPORATION (US) | 1987-04-21 | — | — | US | disclosed |
| EP-0191448-A2 | Antihypertensive dihydropyridine derivatives | SYNTEX (U.S.A.) INC. (US) | 1986-08-20 | — | — | EP | disclosed |
| US-4595690-A | Hypotensive agents | SYNTEX (U.S.A.) INC. (US) | 1986-06-17 | — | — | US | disclosed |
| US-4581470-A | Novel polyols and uses thereof | UNION CARBIDE CORPORATION (US) | 1986-04-08 | — | — | US | disclosed |
| EP-0141253-A1 | Novel polyols and uses thereof | UNION CARBIDE CORPORATION (US) | 1985-05-15 | — | — | EP | disclosed |
| US-4394329-A | PLASTICIZING, EXPLOSIVES, VASODILATION, 2-HYDROXYMETHYL-1,3-PROPANEDIOL NITRATION | THIOKOL CORPORATION (US) | 1983-07-19 | — | — | US | disclosed |
| US-4336408-A | 2-Hydroxymethyl-1,3-propanediol preparation | THIOKOL CORPORATION (US) | 1982-06-22 | — | — | US | disclosed |
| US-4250313-A | HEATING A 2,2,6,6-TETRAMETHYL-4-PIPERIDONE AND A 5-METHYLOL-1,3-DIOXANE | ARGUS CHEMICAL CORP. (US) | 1981-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583861-B2 | Derivatives of imidazo[4,5-d]pyridazine, their preparation and their therapeutic application | TLR7, TLR8, TLR6 | APLNR 691/4885APP 4226/4885 |
| US-20260069539-A1 | LIPIDOID COMPOUNDS AND RELATED COMPOSITIONS AND USES | STARD3, LPCAT3, LPCAT1 | APLNR 2144/4885APP 973/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | APLNR 3014/4885APP 3885/4885 |
| US-20100022778-A1 | PROCESS FOR PRODUCTION OF SULFINYLBENZIMIDAZOLE COMPOUNDS OR SALTS THEREOF | SULT1E1, SULT1A1, SQOR | APLNR 4867/4885APP 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.